2019 | 2018 | 2017 | 2016 | 2015

La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives

01/07/19

- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in Ju

Read More

La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference

01/04/19

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018

10/24/18

SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018

10/18/18

SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

08/08/18

SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from l

Read More

La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA

08/03/18

SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018

08/01/18

SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)

06/25/18

SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from l

Read More

La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association

05/17/18

SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffer

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States

03/22/18

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/15/18

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More

La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock

03/14/18

SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More

GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury

03/06/18

Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018 Manuscript Published Online in Critical Care Medicine SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE

Read More

GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study

02/25/18

Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care Congress SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that an abstract, entitled “

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

02/22/18

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,

Read More

La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study

02/21/18

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for i

Read More

La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)

12/21/17

Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (N

Read More

La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis

12/18/17

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with here

Read More

La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia

12/04/17

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic human hepcidin) in patients with transfusion-depe

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress

10/26/17

SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018

09/25/17

-- Decision follows successful Scientific Advice meeting with European Medicines Agency -- SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2017-- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) toda

Read More

Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

09/20/17

Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Co

Read More

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

08/28/17

– Priority Review Granted – SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) h

Read More

La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501

08/08/17

SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to p

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress

07/27/17

SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

05/21/17

SAN DIEGO--(BUSINESS WIRE)--May 21, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress

04/27/17

SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/23/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 23, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock

03/20/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

02/27/17

-- Primary efficacy endpoint analysis highly statistically significant (p<0.00001) -- Trend toward longer survival observed -- New Drug Application planned for second half of 2017 -- Company to h

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress

02/23/17

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress

11/03/16

SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2016-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffe

Read More

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

10/24/16

SAN DIEGO--(BUSINESS WIRE)--Oct. 24, 2016-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Agreement with European Medicines Agency on Pivotal Study of LJPC-401

09/07/16

-Conference Call at 9:00 AM Eastern Time on Thursday, September 8, 2016 SAN DIEGO--(BUSINESS WIRE)--Sep. 7, 2016-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development o

Read More

La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401

09/07/16

-Dose-dependent, Statistically Significant Reduction in Serum Iron Observed (p=0.008) -LJPC-401 Well Tolerated; No Dose-Limiting Toxicities at Any Dose Level -Conference Call at 9:00 AM Eastern Time on Thur

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2016

08/08/16

SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2016-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffe

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference

06/06/16

SAN DIEGO--(BUSINESS WIRE)--Jun. 6, 2016-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patient

Read More

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress

05/06/16

SAN DIEGO--(BUSINESS WIRE)--May 6, 2016-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffer

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Cowen and Company 36th Annual Health Care Conference

03/03/16

SAN DIEGO--(BUSINESS WIRE)--Mar. 3, 2016-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patient

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2015 Financial Results and Highlights Corporate Progress

02/25/16

SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2016-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2016 BIO CEO & Investor Conference

01/29/16

SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2016-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

11/30/15

Patent Term Extends to 2034 SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to s

Read More

La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results and Recent Corporate Progress

11/06/15

SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2015-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patient

Read More

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload

10/19/15

SAN DIEGO--(BUSINESS WIRE)--Oct. 19, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Closes Offering of Common Stock

09/15/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 15, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

09/11/15

EMA Innovation Task Force Meeting Granted SAN DIEGO--(BUSINESS WIRE)--Sep. 11, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies in

Read More

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock

09/10/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 10, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock

09/09/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 9, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva

08/18/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

08/18/15

Novel Compounds Have Therapeutic Potential in Broad Range of Diseases, Including Certain Rare Genetic Disorders SAN DIEGO & NASHVILLE, Tenn.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla),

Read More

La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401

08/11/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results and Recent Corporate Progress

08/07/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb

08/05/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

Lakhmir S. Chawla, M.D. Receives the International Vicenza Award

07/01/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the JMP Securities Life Science Conference 2015

06/17/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

a Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2015 Global Healthcare Conference

05/27/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Acquires Rights to Next-Generation Gentamicin Derivatives

05/07/15

Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended

Read More

La Jolla Pharmaceutical Company Announces Portfolio Reprioritization

05/07/15

Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended

Read More

La Jolla Pharmaceutical Company Announces First Quarter 2015 Financial Results and Corporate Highlights

04/29/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer

04/27/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board

04/22/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-thr

Read More

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

04/06/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension

03/24/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease

03/18/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights

03/16/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension

02/09/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

02/04/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement

12/09/14

License Covers Intellectual Property Relating to LJPC-501 SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intende

Read More

Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week

11/12/14

Primary Endpoint Met; Statistically Significant Improvement in Kidney Function Observed Improvement More Pronounced in Diabetic Patients Results Reproduced in Extension Study PHILADELPHIA--(BUSINESS WIRE)--La Jolla Pharmaceutical Company

Read More

La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights

11/12/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week

10/23/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“the Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference

09/08/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome

08/25/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today

Read More

La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results

08/14/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today

Read More

La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation

08/14/14

Patent Covers Chronic Inflammatory Diseases such as Non-Alcoholic Steatohepatitis (NASH) and Chronic Kidney Disease (CKD) SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a lea

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference

08/11/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George

Read More

La Jolla Pharmaceutical Company Closes Offering of Common Stock

07/28/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing

Read More

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock

07/23/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock

07/22/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its i

Read More

La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)

07/15/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pr

Read More

La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension

07/08/14

Application for Orphan Drug Designation Filed SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet,

Read More

La Jolla Pharmaceutical Company Strengthens Board of Directors with Appointment of Robert H. Rosen

07/07/14

SAN DIEGO, Calif.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the

Read More

La Jolla Pharmaceutical Company Added to the Russell Microcap Index

06/30/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 BIO International Convention

06/19/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare Conference

06/18/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George

Read More

La Jolla Pharmaceutical Company Enters into Agreement With Stanford University for New Drug Delivery Technology

06/16/14

Novel Formulations Currently Being Tested in Animal Models of NASH SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting

Read More

La Jolla Pharmaceutical Company Announces Completion of Enrollment of Phase 2 Extension Study of GCS-100 in Chronic Kidney Disease

06/04/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference

05/28/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George

Read More

La Jolla Pharmaceutical Company Announces First-Quarter 2014 Financial Results

04/30/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”) a leader in the development of therapeutics targeting significant unmet life-threatening diseases announces first-quarter 2014

Read More

La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress

03/31/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter

Read More

La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin

03/31/14

Dosage Forms of Purified Modified Pectin with Molecular Weight Range of 10-250 kilodaltons Covered Patent Covers Chronic Inflammatory Diseases including Chronic Kidney Disease and NASH SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical

Read More

La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress

03/31/14

SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter and full-year 201

Read More

La Jolla Pharmaceutical Company Reports Positive, Top-Line Results from Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease

03/10/14

Primary Efficacy Endpoint of Improved Kidney Function Achieved GCS-100 Well-tolerated Conference Call and Webcast at 8:30 AM Eastern Time on Tuesday, March 11 SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (th

Read More

La Jolla Pharmaceutical Company to Present at 26th Annual ROTH Growth Stock Conference

03/05/14

GCS-100 Phase 2 Clinical Trial Update will be Presented SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significa

Read More

La Jolla Pharmaceutical Company and the George Washington University Enter Into Agreement for Technology Related to LJPC-501

02/27/14

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that i

Read More

La Jolla Pharmaceutical Company Announces Final Dosing in Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease

02/21/14

Study Protocol for Phase 2 Clinical Study and Extension Study Released on Website SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeut

Read More

La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation

02/20/14

Treatment of Inflammatory Diseases Such as Non-Alcoholic Steatohepatitis (NASH) Covered SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therap

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts